Proprietary Diagnostic Platform Built for Clinical Scale
Core Technologies
High-resolution detection of circulating tumor cells using proprietary signal amplification techniques.
CTC-Sense™ Platform
Enables enrichment and identification of clinically significant tumor cells from peripheral blood.
Molecular Layer (miRNA / qPCR)
Adds biological specificity and risk stratification beyond imaging alone.
Your Patients Deserve a Clearer Answer.
You Deserve a Better Tool.
Partner with 5Q Spectra to bring next-generation, non-invasive prostate cancer detection to your practice, with science, support, and precision tailored to your patients’ needs.
Conventional Prostate Tests Leave Too Much Unanswered.
Every year, thousands of men face invasive biopsies, unnecessary treatments, or missed diagnoses all because standard tests weren't designed to see the full picture.
PSA Blood Test
The most widely used screening tool, yet it cannot distinguish between cancer and benign conditions, leading to overtreatment and anxiety.
Prostate Biopsy
Considered the diagnostic gold standard, yet it is invasive, painful, prone to sampling error, and carries real infection risk.
Circulating Tumor Cells
A promising liquid biopsy approach, but limited by sensitivity and reliance on cancer-specific markers that may not be present.
Three Tiers of Precision
Each tier builds on the last, adding accuracy, context, and clinical confidence.
Foundation Minimally Invasive Baseline
A next-generation blood test measuring genomic biomarkers (nfDNA, miRNA, cfDNA) from a simple blood draw. Generates a personalized risk score with significant predictive power, no biopsy required at this stage.
Enhanced MRI /Ultrasound Integration
Builds on the foundation tier by adding MRI or ultrasound imaging data, dramatically improving detection accuracy and enabling precise anatomical risk stratification.
T3 Premium Full Multi-Modal Risk Stratification
The complete picture. Combines all prior layers with full-spectrum genomic analysis, clinical history, and advanced AI modeling to deliver a comprehensive, actionable risk stratification report for the treating clinician.
5Q Spectra’s platform is built on peer-validated biomarker science and multi-modal AI, giving clinicians deeper data than any single test can provide.
Biomarker Classes
nfDNA · miRNA · cfDNA measured simultaneously for richer signal
Imaging Integration
Structural imaging fused with liquid biopsy data for anatomical precision
Risk Stratification
Machine-learning model trained on multi-modal clinical datasets
Unnecessary Biopsies
The goal: clinical clarity before any invasive procedure is ordered
ProstateDxTM is only the beginning.
Transformative, non-invasive test with the potential for global screening adaptation and long term healthcare impact.
Have any questions?
What makes ProstateDx™ (PSB) different from traditional prostate cancer screening ?
Traditional prostate cancer screening starts and often stops with PSA, a useful but blunt tool. A high PSA can signal cancer, but it can also mean an enlarged prostate, inflammation, or simply nothing at all. It doesn't tell your doctor what is actually happening at a biological level. That uncertainty is what leads to unnecessary biopsies, prolonged anxiety, and in some cases, overtreatment of cancers that never needed to be touched. ProstateDx™ goes further. It measures biologically active prostate cancer cells in your blood — the actual biology — and translates that into a clear risk score. It's not guessing based on a number. It's reading the signal your body is already sending. The result is a smarter, less invasive path to the answer you actually need.
Is the test invasive?
Not at all. ProstateDx™ is a simple blood draw the same kind you'd get at any routine doctor's visit. No needles beyond that, no prep, no recovery time. That's exactly the point. Before ProstateDx™ the next step after an elevated PSA was often a biopsy, an uncomfortable, anxiety-inducing procedure that, up to 70% of the time, comes back negative. ProstateDx™ was built to change that. One blood draw can give your doctor the biological clarity they need, so a biopsy only happens when it truly should.
What do the results tell me?
ProstateDx™ gives you and your doctor a single, easy-to-understand risk score from 0 to 100 that estimates the likelihood of clinically significant prostate cancer. It's not a yes or no answer, but it is something far more useful: a biologically grounded signal that helps your doctor decide whether a biopsy is truly necessary. A lower score means you may be able to skip the biopsy altogether and simply continue monitoring. A higher score means your doctor has the confidence to act without second-guessing a number alone. Either way, you leave with clarity, not more uncertainty.
Who should consider this test?
Patients who have elevated or unclear screening results, family history concerns, or questions about cancer risk may benefit from additional biological insight. Your physician can help determine whether the test is appropriate for your situation.
ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed as a laboratory developed test (LDT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.